ClinicalTrials.gg

Program

Fluorine F 18 FPyQCP

Its studies are mostly in Colorectal Neoplasms, led by Bracco.

Furthest: phase 2, since Feb 10, 20261 company-led study, 1 open or runningNext primary completion: Jan 31, 2028 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Bracco11 open or runningphase 2since Feb 10, 2026Feb 10, 2026Jan 31, 2028phase 2 · NCT07432633

Also a collaborator on its studies: Medpace.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Feb 10, 2026First study: phase 2 study in Colorectal NeoplasmsFirst studyNCT07432633 · 71 planned · United States

Ahead

  1. Jan 31, 2028Primary completion: phase 2 study in Colorectal NeoplasmsNCT07432633

TargetBeta

FAP →read by rule
“A fibroblast activation protein (FAP)-targeted tracer ”NCIt, by rule

Other programs on FAP

ProgramCompanyFurthest phaseStudies
Lutetium-177Novartisphase 324
Gallium-68Philogenphase 317
Fluorine F 18 FAPI-74rulesofiephase 33
HRS-6768Jiangsu HengRui Medicinephase 21
Anti-FAP Antibody-drug Conjugate OMTX705ruleoncomatryx-biopharma-s-lphase 12
Gallium Ga 68 NNS309Novartisphase 12
Actinium Ac 225 RTX-2358ruleratio-therapeutics-incphase 11
Lutetium Lu 177-labeled FAP-targeting Ligand LY4337713ruleEli Lillyphase 11
Lutetium Lu 177-labeled FAP-targeting Ligand IM-3050ruleImmunomephase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07432633Colorectal Neoplasms · United States2RecruitingJan 31, 202871

How it is read

Names in the registry

  • “[18F]FPyQCP”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.